Med Consult: Surgery & Family Medicine

31/12/2024

16/08/2024

IF you want to prevent FATTY LIVER ..

Three things to AVOID (bads):
1. Juice, sodas, soft drinks, diet sodas w/ espartane
2. Deep fried foods (fries, fried chicken, etc)
Air fryer is better
3. Process - chips, sugary cereals, candies,
hotdogs, instant noodles, etc

Three things to CONSUME if you have (Goods):
1. Beverages - black coffee, matcha, green tea
2. Turmeric - 1/2 - 1 tsp/day in soups, food
3. Ginger - 1/2 in. of root

👍

07/06/2023

Moderate your eating of bread, pasta, rice and any sweetened juice.

11/07/2022

Regularly practicing & techniques in the WHO stress management guide can help you find peace of mind & meaning in your life even during times of high stress. Click the [link] below to download the Illustrated guide in PDF format.

https://apps.who.int/iris/rest/bitstreams/1276043/retrieve

30/06/2022

WHO stress management guide helps people recognize the physical signs of stress e.g.
❗️Headache
❗️Neck & shoulder pain
❗️Upset stomach
❗️Heavy chest, etc.

Advice for coping with stress https://bit.ly/WHOStressManagement

12/02/2022

One year ago, a friend posted this.

Many of us been using 2 medical masks; others would even use medical mask on top of N95.

CDC just proved in a study: 2 masks better than 1.

Just make sure you can breathe well and that you don't feel dizzy or restless nor have headaches or can't concentrate well, because these are signs you have low levels of oxygen.

Stay safe and practice social distancing.
😷 🦠

09/02/2022

30/11/2021

Understanding Covid:

Covid virus is back .. repeating its old trick - mutating again, called OMICRON.

Trick or treat? Another scare and lockdown?

Vaccination can still help to prevent infection of covid19 and previous variants.

So, stay healthy and keep safe:
1. wear surgical mask, NOT cloth masks.
2. practice physical distance of at least 1 meter and
3. avoid unnecessary crowded places, especially indoors. Open air is better.

❤️
https://www.facebook.com/100000282377252/posts/4976479302371433/?

27/10/2021

05/10/2021

About IVERMECTIN

There was a randomized clinical trial of ivermectin in patients with mild forms of COVID-19 that was published in JAMA in March 2021. That study analyzed 476 patients.

OBJECTIVE:
To determine whether ivermectin is an efficacious treatment for mild COVID-19.

DESIGN, SETTING, and PARTICIPANTS
Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state’s health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020.

INTERVENTION:
Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200).

MAIN OUTCOMES and MEASURES:
Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected.

RESULTS:
Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group).

https://jamanetwork.com/journals/jama/fullarticle/2777389

This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.

25/08/2021

Understanding Covid:
COVID Early treatment, published in the American Journal of Medicine

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Peter A. McCullough, MD, MPH
Ronan J. Kelly, MD
Gaetano Ruocco, MD
William W. O'Neill, MD
Marcus Zervos, MD
Harvey A. Risch, MD, PhD

Open Access Published:
August 06, 2020
DOI:https://doi.org/10.1016/j.amjmed.2020.07.003

https://www.amjmed.com/article/S0002-9343%2820%2930673-2/fulltext

Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and executio...